Effects of 5-Campestenone (24-Methylcholest-5-en-3-one) on the Type 2 Diabetes Mellitus Model Animal C57BL/KsJ-db/db Mice

Summary

We examined the therapeutic effects of dietary exposure to 5-campestenone (24-methylcholest-5-en-3-one), an enone derivative of campesterol, in C57BL/KsJ-db/db mice, which are an animal model of obese type 2 diabetes. Blood glucose levels of db/db mice linearly increased from 270 to 720 mg/dl in 10 weeks, an approximately 7-fold difference from the levels of db/+m mice. The 0.3 % dietary exposure to 5-campestenone caused a marked reduction in blood glucose levels of 330 mg/dl after 10 weeks of feeding with a concomitant inhibition of glucose excretion in urine. Only slight efficacy was observed with 0.1 % dietary exposure to this chemical in db/db mice. Significant decreases of plasma triglyceride and plasma free fatty acid were also observed in db/db mice at a 0.3 % dose. However, feed efficiency and body-weight gain in db/db mice was improved by 5-campestenone. No obvious anomaly due to consumption of 5-campestenone was detected by necropsy or clinical observation.

Key words

5-Campestenone - Type 2 Diabetes Mellitus Model Animal - C57BL db/db Mouse - Hypoglycemic Activity - Plasma Insulin

References

• 1 Lee Y, Hirose H, Ohneda M, Johnson J H, MacGarry J D. Beta-cell lipotoxicity in the pathogenesis of non-insulin-dependent diabetes mellitus of obese rats: Impairment in adipocyte-beta-cell-relationships. Proc Natl Acad Sci.  USA. 1994;  91 10878-10882
• 2 Randle P J, Arland P B, Hales C N, Newsholme E A. The glucose fatty-acid cycle: Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus.  Lancet. 1963;  1 785-789
• 3 Boden G. Role of fatty acids in the pathogenesis of insulin resistance and NIDDM.  Diabetes. 1997;  46 3-10
• 4 Suzuki K. Anti-obesity effect of cholest-4-en-3-one, an intestinal catabolite of cholesterol, on mice.   J Nutr Sci Vitaminol. 1993;  39 537-543
• 5 Suzuki K, Shimizu T, Nakata T. The cholesterol metabolite cholest-4-en-3-one and its 3-oxo derivatives suppress body weight gain, body fat accumulation and serum lipid concentration in mice.   Bioorg Med Chem Lett. 1998;  8 2133-2138
• 6 Suzuki K, Shimizu T, Nakata T. A medicament for treating and improving lipid metabolism. US patent 09/480 892. 2000
• 7 Parish E J, Luo C, Parish S, Heideprien R W. Selective oxidation of steroidal homoallylic alcohols usig pyridium chlorochromate (PPC).  Synthetic Communications. 1992;  22 2839 -2847
• 8 Arakawa K, Ishihara T, Oku A, Nawano M, Ueta K, Kitamura K, Matsumoto M, Saito A. Improved diabetic syndrome in C57BL/Ksj-db/db mice by oral administration of the Na⁺-glucose cotransporter inhibitor T-1095.   British J Pharmacol. 2001;  132 578-586
• 9 Tutwiler G F, Kirsch T, Bridi G. A pharmacologic profile of McN-3495[N-(1-methyl-2-pyrrolidinylidene)-N′-phenyl-1-pyrrolidinecarboximidamide], a new, orally effective hypoglycemic agent.  Diabetes. 1978;  27 856-867
• 10 Sugiyama Y, Taketomi S, Tawada H, Meguro K, Ikeda H, Fujita T. Selective potentiation of 5-methyl-2-(1-methylcyclohexyl)-4-oxazoleacetic acid (AD-4610) on glucose-induced secretion.   Horm Metab Res. 1988;  20 145-149
• 11 Ikeda H, Taketomi S, Sugiyama Y, Shimura Y, Sohda T, Meguro K, Fujita T. Effects of pioglitazone on glucose and lipid metabolism in normal and insulin resistant animals.  Arznein-Forsch/ Drug.. Res.1990;  40 (I) 156-162
• 12 Sugiyama Y, Taketomi S, Shimura Y, Ikeda H, Fujita T. Effects of pioglitazone on glucose and lipid metabolism in Wistar fatty rats.  Arznein-Forsch/Drug Res. 1990;  40 (I) 263-267